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We conducted a test-negative case–control study 
based in five European sentinel surveillance networks. 
The early 2012/13 adjusted influenza vaccine effective-
ness was 78.2% (95% CI: 18.0 to 94.2) against influ-
enza B, 62.1% (95% CI: −22.9 to 88.3%) against A(H1)
pdm09, 41.9 (95% CI: −67.1 to 79.8) against A(H3N2) 
and 50.4% (95% CI: −20.7 to 79.6) against all influenza 
types in the target groups for vaccination. Efforts to 
improve influenza vaccines should continue to better 
protect those at risk of severe illness or complications.
Background
Since 2008/9, the Influenza Monitoring Vaccine 
Effectiveness (I-MOVE) network has estimated the 
effectiveness of seasonal influenza vaccine to prevent 
medically attended influenza-like illness (ILI) labora-
tory confirmed as influenza [1-7]. One of the compo-
nents of I-MOVE is a multicentre case–control study 
based on practitioners participating in the European 
Influenza Surveillance Network (EISN) [8].
This season, six study sites are participating in the 
multicentre study: Germany, Ireland, Poland, Portugal, 
Romania and Spain.
Here we provide early season estimates of the 2012/13 
influenza vaccine based on data collected from week 
43 2012 to week 3 2013. Poland is not included in the 
early season estimates as there were no vaccinated 
individuals among the patients recruited.
Estimating influenza vaccine effectiveness
The methods of the multicentre case–control study 
have been described previously [1-4,9].
Participating practitioners swabbed and interviewed 
all or a systematic sample of patients consulting for 
ILI. The common variables collected in all study sites 
were symptoms, date of onset and swabbing, 2012/13 
seasonal vaccination status and date of vaccination, 
sex, age, presence of chronic conditions and number 
of hospitalisations for the chronic condition in the past 
12 months. Four of the five study sites included a ques-
tion on belonging to the target groups for vaccination. 
In Portugal, this information was gathered using infor-
mation on age, chronic conditions, pregnancy, whether 
the patient was a health professional or carer and a 
household member or carer of an at-risk patient aged 
less than six months.
In the pooled analysis, we included patients with a 
nasopharyngeal swab taken less than eight days after 
symptom onset and meeting the European Union case 
definition for ILI: sudden onset of symptoms, at least 
one of four systemic symptoms (fever or feverishness, 
malaise, headache, myalgia) and at least one of three 
respiratory symptoms (cough, sore throat, shortness 
of breath) [10]. A case of confirmed influenza was an 
ILI patient who was swabbed and tested positive for 
influenza virus using real-time reverse-transcription 
polymerase chain reaction or culture. Controls were ILI 
patients who tested negative for any influenza virus.
We defined a person as vaccinated if he or she had 
received at least one dose of a 2012/13 seasonal influ-
enza vaccine more than 14 days before ILI symptom 
onset. All the others were classified as unvaccinated.
For each study site we included ILI patients with symp-
tom onset up to the end of week 3 2013 and more than 
14 days after the start of national or regional influenza 
vaccination campaigns.
We conducted a complete case analysis excluding 
individuals with missing information on key confound-
ers. We estimated the pooled seasonal influenza vac-
cine effectiveness (VE) as 1 minus the odds ratio (OR) 
expressed as a percentage, using a one-stage method 
with the study site as fixed effect in the model.
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We used a logistic regression model to adjust for pres-
ence of at least one chronic disease, sex, age group 
and month of symptom onset.
We estimated VE against all laboratory-confirmed 
influenza, and individually against influenza A(H3N2), 
A(H1N1)pdm09 and influenza B. For each study site, we 
excluded controls with symptom onset in the weeks 
before symptom onset of the first influenza type/
subtype case depending on the outcome used. We 
also estimated VE restricted to the target groups for 
vaccination.
Early estimates of 2012/13 influenza vaccine 
effectiveness
In the five countries, the influenza season, as defined 
by national thresholds, started at different times – in 
week 50 2012 in Germany and Ireland, week 3 2013 in 
Spain and Romania (Table 1). In week 3, the ILI inci-
dence in Portugal was still below the threshold defin-
ing the start of the season. The first study site to 
recruit cases was Germany (in week 43 2012) and the 
last Romania (in week 2 2013).
Among 554 practitioners, 223 recruited at least one ILI 
patient (Table 1).
Of the 1,161 ILI patients enrolled, 271 tested positive 
for influenza A (23.3%), 162 for influenza B (14.0%) and 
one tested positive for both influenza B and influenza 
A(H1)pdm09. Among the 269 influenza A viruses that 
could be subtyped, 146 (54.3%) were A(H1)pdm09 and 
123 (45.7%) were A(H3N2). Influenza A virus was pre-
dominant in Germany, and influenza B in Ireland and 
Spain (Table 2).
The proportion of patients who were vaccinated was 
2.9% (12/416) among cases and 7.5% (53/705) among 
controls.
After excluding patients with missing information 
on 2012/13 influenza vaccination (n=40), age (n=2), 
sex (n=11), presence of chronic conditions (n=62), we 
included 1,046 individuals (396 cases and 650 con-
trols) in the complete case analysis (Figure). There 
were 12 vaccinated cases: five positive for influenza 
A(H3N2), four for A(H1)pdm09 and three for B. 
The adjusted VE was 62.2% (95% CI: 21.1 to 81.9) for 
influenza A and B combined, 78.2% (95% CI: 18.0 to 
94.2) for influenza B, 62.1% (95% CI: −22.9 to 88.3) 
for A(H1)pdm09 and 41.9 (95% CI: −67.1 to 79.8) for 
A(H3N2) (Table 3). Among the target groups for vacci-
nation, the VE against influenza A and B combined was 
50.4% (95% CI: −20.7 to 79.6).
Discussion
These early estimates suggest a moderate VE against 
all influenza viruses. By type and subtype, the high-
est VE was against influenza B and the lowest against 
influenza A(H3N2).
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Table 2
Details for influenza B (n=163), A(H3N2) (n=123), A(H1)pdm09 (n=146) cases and controlsa (n=727) considered for mid-
2012/13 season trivalent influenza vaccine effectiveness analysis, study sites in five European Union countries, week 
40/2012–week 3/2013 (n=1,161b,c) 
Variables Number of test-negative controlsC/total n (%)
Number of influenza B 
casesb/total n (%)
Number of influenza 
A(H3N2) cases/total 
n (%)
Number of influenza 
A(H1)pdm09 casesb/
total n (%)
Median age (years) 20 31 11 25.5
Age groups (years)
0–4 184/725 (25.4) 16/163 (9.8) 33/123 (26.8) 25/146 (17.1)
5–14 130/725 (17.9) 51/163 (31.3) 38/123 (30.9) 35/146 (24.0)
15–59 350/725 (48.3) 84/163 (51.5) 41/123 (33.3) 79/146 (54.1)
≥60 61/725 (8.4) 12/163 (7.4) 11/123 (8.9) 7/146 (4.8)
Sex
Female 368/714 (51.5) 84/162 (51.9) 56/122 (45.9) 85/146 (58.2)
Days between symptom onset and swabbing
0 60/727 (8.3) 6/163 (3.7) 2/123 (1.6) 8/146 (5.5)
1 294/727 (40.4) 34/163 (20.9) 52/123 (42.3) 55/146 (37.7)
2 171/727 (23.5) 41/163 (25.2) 34/123 (27.6) 37/146 (25.3)
3 112/727 (15.4) 43/163 /26.4) 17/123 (13.8) 23/146 (15.8)
4–7 90/727 (12.4) 39/163 (23.9) 18/123 (14.6) 23/146 (15.8)
Seasonal vaccinationd 2012/13 53/705 (7.5) 3/161 (1.9) 5/117 (4.3) 4/136 (2.9)
At least one chronic condition 143/676 (21.2) 29/161 (18.0) 14/114 (12.3) 18/134 (13.4)
At least one hospitalisation 
in the previous 12 months for 
chronic conditions
11/584 (1.9) 2/152 (1.3) 2/103 (1.9) 0/122 (0.0)
Belongs to target groups for 
vaccination 175/711 (24.6) 35/163 (21.5) 22/117 (18.8) 23/143 (16.1)
Study sites
Germany 578/727 (79.5) 51/163 (31.3) 112/123 (91.1) 122/146 (83.6)
Ireland 45/727 (6.2) 66/163 (40.5) 9/123 (7.3) 5/146 (3.4)
Portugal 33/727 (4.5) 4/163 (2.5) 0/123 (0.0) 6/146 (4.1)
Romania 3/727 (0.4) 2/163 (1.2) 0/123 (0.0) 2/146 (1.4)
Spain 68/727 (9.4) 40/163 (24.5) 2/123 (1.6) 11/146 (7.5)
a Controls used to compare with all influenza cases. 
b One influenza case positive for influenza B and for influenza A(H1)pdm09 was included in both analyses. 
c The virus from three influenza A cases could not be subtyped: these cases are not included in the descriptive analysis.
d Vaccination more than 14 days before onset of influenza-like illness symptoms.
Table 3
Pooled crude and adjusted 2012/13 seasonal vaccine effectiveness against laboratory confirmed influenza by influenza type/
suptype, overall and among target groups for vaccination. Multicentre case–control study in five European Union study 
sites, week 43 (2012)–week 3 (2013), influenza season 2012/13
Influenza type/subtype Crude vs adjusted model
Cases and controls 
(n/n)
Vaccinated cases and 
controls (n/n)
Vaccine effectiveness 
(%)
95% confidence 
intervals
All population
A and B
Crudea 396/650 12/48 62.8 27.3 to 80.9
Adjustedb 396/650 12/48 62.2 21.1 to 81.9
A(H1)pdm09
Crudea 125/477 4/37 66.1 -2.7 to 88.8
Adjustedc 125/477 4/37 62.1 -22.9 to 88.3
A(H3N2)
Crudea 111/577 5/39 34.7 -70.1 to 74.9
Adjustedb 111/577 5/39 41.9 -67.1 to 79.8
B
Crudea 158/523 3/41 79.8 29.2 to 94.2
Adjustedb 158/523 3/41 78.2 18.0 to 94.2
Target population
A and B
Crudea 73/157 9/32 46.5 -23.0 to 76.8
Adjustedd 73/154 9/32 50.4 -20.7 to 79.6
a Study site included in the model as fixed effect.
b Model adjusted for presence of at least one chronic disease, sex, 10-year age group and month of symptom onset.
c Model adjusted for presence of at least one chronic disease, sex, 10-year age group until age 60, where age is coded as ≥60 years and 
month of symptom onset.
d Model adjusted for presence of at least one chronic disease, sex, age group (0–14; 15–59 and ≥60 years) and month of symptom onset. 
Three records were excluded for October.
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During the study period, as of week 3-2013, two of the 
participating countries reported a low ILI/ARI activ-
ity (Portugal, Romania) and three medium activity 
(Germany, Ireland, Spain) [11].The sample size varied 
by study site. As most patients (863/1,161, 74.3%) were 
enrolled in Germany, the pooled estimates are highly 
influenced by the German data. When restricting 
the analysis to Ireland, Portugal, Romania and Spain 
(n=296, four vaccinated cases), the adjusted point VE 
against all influenza was higher (73.5%; 95% CI: 8.7 
to 92.3) than the adjusted point VE including the five 
study sites.
As in 2011/12, the results suggests a low-to-moder-
ate VE for influenza A(H3N2) [9]. Our point estimate 
is lower than that reported by Canada [12] and the 
United States [13], countries with a predominance of 
this subtype in the early phase of the 2012/13 sea-
son. Most of the influenza A(H3N2) cases included in 
our study were German patients. In Germany, most of 
Figure
Flowchart of data exclusion for pooled analysis, I-MOVE multicentre case–control study, influenza season 2012/13
EU: European Union; ILI: influenza-like illness; I-MOVE: Influenza Monitoring Vaccine Effectiveness; ISO: International Organization for 
Standardization.
Number of records received for pooled analysis:
1,622
Excluding records:
1,161
Excluding records with missing data from covariates for complete case analysis:
Controls: 727 Cases: 434
1,046
Controls: 650 Cases: 396
Excluding records with missing 2012/13 influenza vaccination status (n=40):
1,121
Controls: 705 Cases: 416
•   Persons with contraindications against vaccination (n=0)
•   Persons administered antivirals before swabbing (n=2)
•   Persons with missing laboratory results (n=0)
•   Persons with date of symptom onset <15 days after start of vaccination 
campaign (n=0)
•   Persons not meeting the EU ILI case definition (n=296)
•   Persons with interval between onset of symptoms and swabbing >7 days or 
exact date of onset not known (n=75)
•   Persons who are controls presenting before ISO week of first influenza case 
and after ISO week of last influenza case (weeks of symptom onset) (n=88)
•   Persons with missing information on age (n=2)
•   Person with missing information on sex (n=11)
•   Persons with missing information on chronic conditions (n=62)
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the 103 influenza A(H3N2) viruses characterised at the 
national reference centre for influenza were similar to 
the A/Victoria/361/2011(H3N2) vaccine virus for the 
2012/13 season [14]. This similarity was also reported 
by the Community Network of Reference Laboratories 
for Human Influenza in Europe (CNRL) [15]. This dis-
crepancy between the apparently well-matched vac-
cine strain/circulating strains and low VE has also been 
noted this season in Canada [12].
Our 2013 early point VE estimates for influenza B are 
similar to estimates from the United States [13] and 
higher than those reported in the United Kingdom [16]. 
All the influenza B virus isolates genetically character-
ised from influenza cases enrolled in the Irish (three 
isolates), Portuguese (three isolates) and Spanish (four 
isolates) study sites were B/Yamagata, the lineage 
included in the 2012/13 vaccine. Data from the German 
national reference centre for influenza indicated that 
among 75 influenza B strains characterised, 68 were 
Yamagata and 7 Victoria.
The sample size did not allow VE estimation by type and 
subtype among the target population for vaccination. 
The low VE against all influenza types in this popula-
tion is similar to the estimates the I-MOVE multicentre 
case–control study provided last season against influ-
enza A(H3) [3].
This season, in which different influenza viruses are 
co-circulating in Europe, the I-MOVE multicentre case–
control study provided early adjusted VE estimates 
for influenza B, A(H3N2) and A(H1N1)pdm09 viruses. 
However, due to small sample size, the precision 
around these estimates is low and should be taken into 
account when interpreting these preliminary results.
The results underscore the importance of providing 
early VE estimates against virus subtype regardless of 
the reported relatedness between circulating viruses 
and administered vaccines. The early VE estimates 
could be useful when defining the recommendations 
for next season’s vaccine composition.
In conclusion, our early season estimates suggest that 
the 2012/13 influenza vaccine is effective in prevent-
ing medically attended laboratory-confirmed influ-
enza, with a higher VE against influenza B than against 
influenza A subtypes. The lower VE among the target 
groups and against influenza A(H3N2) underlines that 
efforts to improve the influenza vaccine should con-
tinue in order to better protect those at risk of severe 
illness or complications.
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